Scientific Sessions 2025  /  HFpEF and CKM Syndrome: Overlap, Interplay and Opportunities to Optimize Outcomes  /  Addressing the ubiquity of excess adiposity in HFPEF
Logo

American Heart Association

  30
  0

Final ID:

Addressing the ubiquity of excess adiposity in HFPEF

  • Vest, Amanda  ( HRMC , Lake havasu city , Arizona , United States )
  • Borlaug, Barry  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Butler, Javed  ( Baylor Scott and White Research , Dallas , Texas , United States )
    • Author Disclosures:
    Amanda Vest: No Answer | Barry Borlaug: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH/NHLBI:Active (exists now) ; Consultant:Tin Alley Ventures:Active (exists now) ; Consultant:VADovations:Active (exists now) ; Consultant:ShouTi:Active (exists now) ; Consultant:NGMBio:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Aria:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Tenax Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Rivus Pharmaceuticals:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Research Funding (PI or named investigator):Corvia:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Axon:Active (exists now) ; Research Funding (PI or named investigator):DoD:Active (exists now) | Javed Butler: DO have relevant financial relationships ; Consultant:Abbott :Active (exists now) ; Consultant:Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:CVRx:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Cardior:Active (exists now) ; Consultant:Cardiac Dimension:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:AskBio:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:American Regent:Active (exists now) ; Consultant:Adaptyx:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

HFpEF and CKM Syndrome: Overlap, Interplay and Opportunities to Optimize Outcomes

Saturday, 11/08/2025 , 03:15PM - 04:30PM

Cardiovascular Seminar

More abstracts on this topic:
From clinical trials to practice: refining the care model for HFpEF

Vaduganathan Muthiah, Butler Javed

The multisystem underpinnings of HFpEF and CKM syndrome

Ho Jen, Sharma Kavita

More abstracts from these authors:
PRO: Lightening the Load: Use of GLP-1 Receptor Agonists in Heart Failure

Vaduganathan Muthiah, Borlaug Barry

Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial

Borlaug Barry

You have to be authorized to contact abstract author. Please, Login
Not Available